SEC 13F Intelligence

Versant Venture Management, LLC / CRNX

Versant Venture Management, LLC’s Crinetics Pharmaceuticals In Position

Does Versant Venture Management, LLC own Crinetics Pharmaceuticals In (CRNX)? Not currently — the last reported position was 410.4K shares worth $9M in Q1 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$9M
Q1 2022
Shares
410.4K
% of Portfolio
+8.99%
Quarters Held
8
position exited

Position History CRNX

Reported value by quarter
Q2 ’20: $35.6BQ2 ’20Q3 ’20: $32MQ3 ’20Q4 ’20: $29MQ4 ’20Q1 ’21: $31MQ1 ’21Q2 ’21: $15MQ2 ’21Q3 ’21: $17MQ3 ’21Q4 ’21: $12MQ4 ’21Q1 ’22: $9MQ1 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2022410.4K$9M+8.99%
Q4 2021410.4K$12M+6.24%
Q3 2021820.7K$17M+7.15%
Q2 2021820.7K$15M+5.13%
Q1 20212.03M$31M+6.05%
Q4 20202.03M$29M+2.98%
Q3 20202.03M$32M+5.82%
Q2 20202.03M$35.6B+5.11%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Versant Venture Management, LLC’s full portfolio or all institutional holders of CRNX.